In the past week, ENSC stock has gone up by 6.45%, with a monthly decline of -49.23% and a quarterly plunge of -70.67%. The volatility ratio for the week is 17.56%, and the volatility levels for the last 30 days are 12.73% for Ensysce Biosciences Inc The simple moving average for the last 20 days is -25.63% for ENSC stock, with a simple moving average of -67.21% for the last 200 days.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
Moreover, the 36-month beta value for ENSC is 1.18. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENSC is 1.69M and currently, short sellers hold a 1.86% of that float. On April 15, 2025, ENSC’s average trading volume was 41.40K shares.
ENSC) stock’s latest price update
Ensysce Biosciences Inc (NASDAQ: ENSC) has seen a rise in its stock price by 1.02 in relation to its previous close of 1.96. However, the company has experienced a 6.45% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-15 that ~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced completion of Part 1 of its second clinical trial to evaluate PF614-MPAR for overdose protection. PF614-MPAR-102 demonstrated that the combined Ensysce TAAPTM and MPAR® technologies can deliver strong relief for severe pain yet protect from the risk of excessive doses when consumed accidentally or deliberately.
ENSC Trading at -53.27% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.50% of loss for the given period.
Volatility was left at 12.73%, however, over the last 30 days, the volatility rate increased by 17.56%, as shares sank -45.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -67.88% lower at present.
During the last 5 trading sessions, ENSC rose by +13.97%, which changed the moving average for the period of 200-days by -73.63% in comparison to the 20-day moving average, which settled at $2.6695. In addition, Ensysce Biosciences Inc saw -75.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -13.8 for the present operating margin
- -0.94 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -16.38. The total capital return value is set at -1.99. Equity return is now at value -471.82, with -192.33 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -24.87. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -5.22.
Currently, EBITDA for the company is -6.73 trillion with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of 7.03. The receivables turnover for the company is 3.93for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.42.
Conclusion
To wrap up, the performance of Ensysce Biosciences Inc (ENSC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
